Organigram Holdings Inc. (NASDAQ:OGI – Free Report) – Analysts at Alliance Global Partners upped their FY2024 earnings estimates for shares of Organigram in a note issued to investors on Monday, December 9th. Alliance Global Partners analyst A. Grey now expects that the company will earn ($0.18) per share for the year, up from their previous estimate of ($0.19). The consensus estimate for Organigram’s current full-year earnings is ($0.21) per share. Alliance Global Partners also issued estimates for Organigram’s Q4 2024 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.02) EPS.
Organigram Trading Down 2.5 %
OGI stock opened at $1.54 on Wednesday. The firm’s 50-day moving average is $1.65 and its two-hundred day moving average is $1.68. Organigram has a 52 week low of $1.20 and a 52 week high of $2.91. The company has a market capitalization of $167.73 million, a price-to-earnings ratio of -3.67 and a beta of 1.02.
Hedge Funds Weigh In On Organigram
Organigram Company Profile
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
See Also
- Five stocks we like better than Organigram
- Trading Stocks: RSI and Why it’s Useful
- UiPath: A Golden Opportunity in AI-Driven Workflow Automation
- Stock Sentiment Analysis: How it Works
- Time to Take Bitcoin Profits as $100K Milestone Nears?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 4 Stocks That Crushed Analyst Estimates by More Than Double
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.